(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193975 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61P 25/08* (2006.01)
A61K 9/10 (2006.01) *A61P 25/16* (2006.01)
A61K 9/16 (2006.01) *A61P 25/28* (2006.01)
A61K 31/122 (2006.01) *A61P 35/00* (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:
PCT/US2025/019817

(22) International Filing Date:
13 March 2025 (13.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2024-039505 13 March 2024 (13.03.2024) JP
114109156 12 March 2025 (12.03.2025) TW

(71) Applicant: **PTC THERAPEUTICS, INC.** [US/US]; 500 Warren Corporate Center Drive, Warren, New Jersey 07059 (US).

(72) Inventors: **ONOUE, Yoshihiro**; c/o Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita-shi, Osaka, Osaka 564-0053 (JP). **NOBUTO, Tomohiro**; c/o Sumitomo Pharma Co., Ltd., 6-8, Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka, Osaka 541-0045 (JP).


(74) Agent: **TAYLOR, Alisha** et al.; Squire Patton Boggs (US) LLP, 555 California Street, Suite 550, San Francisco, California 94104 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: FORMULATIONS FOR STABILIZING DISSOLUTION OF MEDICAMENTS

(57) Abstract: The present disclosure provides a suspension granule formulation with good dissolution characteristics after suspension. Specifically, the present disclosure provides granules containing particles of a compound shown in Formula 1: or a pharmaceutically acceptable salt or solvate thereof, wherein 20% or less by weight of the particles comprising the granule formulation have a particle diameter of 500 μm or more.






Figure 1

[Continued on next page]

WO 2025/193975 A1

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*